Autotransfusion Devices Market Research Report and Outlook by 2028

The autotransfusion devices market is projected to expand from US$ 1,000.26 million in 2021 to US$ 1,331.99 million by 2028, reflecting a compound annual growth rate (CAGR) of 4.2% during the period from 2021 to 2028.

This growth is primarily driven by the increasing prevalence of chronic diseases, a rise in organ transplants, and challenges in sourcing compatible blood types globally. However, the market faces obstacles such as product recalls and inherent risks associated with autotransfusion, which may hinder its expansion.

The COVID-19 pandemic significantly impacted the autotransfusion devices market, leading to a notable decline in revenue. Stringent government restrictions resulted in a decrease in surgical procedures, particularly those involving substantial blood loss, such as orthopedic and cardiac surgeries. For instance, the American Medical Association reported a staggering 48% reduction in total surgical procedures in the U.S. during the pandemic. Nevertheless, as restrictions eased, the volume of surgeries began to normalize.

Recent surges in COVID-19 variants have once again limited surgical operations, particularly in heavily affected regions. Despite these challenges, healthcare facilities are adapting and innovating to provide necessary care. The resumption of postponed surgeries has led to an increased demand for autotransfusion devices, presenting opportunities for market growth through innovative product offerings. For example, the American Association of Orthopaedic Surgeons and the Agency for Healthcare Research and Quality (AHRQ) estimate that approximately 700,000 knee replacements and 450,000 hip replacements are performed annually in the U.S. Additionally, a report from the University of Alabama indicated that around 320,000 coronary artery bypass grafting procedures were conducted in 2020. Thus, while the pandemic negatively affected the North American autotransfusion devices market, it is now regaining momentum and is expected to continue growing in the coming years.

In Europe, the economy has been severely impacted by the rapid rise in COVID-19 cases, particularly in countries like Spain, Italy, Germany, France, and the UK, which have experienced high mortality rates. Since the onset of the pandemic, millions of patients have faced delays in care as hospitals postponed non-urgent surgeries, including those for heart and orthopedic conditions. The British Journal of Surgery reported that an estimated 28,404,603 operations were canceled or postponed during the peak 12 weeks of disruption due to COVID-19, with a cancellation rate of approximately 72-73% during that period.

The aging population and changing lifestyles are contributing to a steady rise in chronic medical conditions. The growing middle-class population and urbanization are leading to more sedentary lifestyles. The World Health Organization (WHO) projected a 57% increase in chronic diseases by 2020. Modernization has reduced physical activity levels and increased stress from various factors, leading to a rise in conditions such as arthritis, cardiovascular diseases, various cancers, diabetes, obesity, and oral health issues among the elderly in developed nations. These chronic diseases pose significant challenges to public health, society, and economies.

In India, the National Institute of Cancer Prevention and Research (NICPR) and the Indian Council of Medical Research (ICMR) estimate that the annual prevalence of cancer is around 2.25 million, necessitating numerous surgical interventions. Autotransfusion devices are extensively utilized in various surgical procedures, particularly in cardiac surgeries and other invasive operations. Chronic conditions such as cancer and cardiovascular diseases are leading causes of mortality worldwide, often requiring surgical procedures that carry the risk of significant blood loss. Autotransfusion devices play a crucial role in managing blood levels during these procedures, thereby driving the growth of the global autotransfusion devices market.

Key players in the market, such as Zimmer Biomet and SARSTEDT AG and Co. KG, are actively pursuing inorganic growth strategies that enhance the autotransfusion devices market. For instance, in December 2020, Zimmer Biomet acquired A&E Medical Corporation for USD 150 million in cash at closing, with an additional USD 100 million payable in 2021. This acquisition included A&E Medical's complete portfolio of sternal closure devices. Similarly, in April 2020, SARSTEDT AG and Co. KG acquired 80% of Timedico A/S, with plans to acquire the remaining 20% in the future, enhancing their value proposition to global customers.

The autotransfusion devices market is categorized by type, application, and end user. In terms of type, the market is divided into products and accessories, with the accessories segment holding the largest market share in 2021 and expected to register the highest CAGR during the forecast period.

Key regulatory and research organizations, including the Food and Drug Administration, Australian Blood Management, Business Monitor International, National Institute of Metrology Standardization and Industrial Quality, National Blood Authority, Northern Ireland Blood Transfusion Service, National Institute of Cancer Prevention and Research, and the Organ Procurement and Transplantation Network, have been referenced in the preparation of this report on the autotransfusion devices market.